Neuropeptide Y (29-64), amide, human
(Synonyms: 神经肽-Y(人,鼠),NPY (human, rat)) 目录号 : GC31165
Neuropeptide Y (29-64), amide, human，一种由36个氨基酸组成的肽，可与五种G蛋白偶联受体（Y1、Y2、Y4、Y5和y6）结合。
Cas No.:90880-35-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Neuropeptide Y (29-64), amide, human, a 36-aa peptide, binds to five G-protein-coupled receptors (Y1, Y2, Y4, Y5, and y6). Widely distributed in the central and peripheral nervous systems as well as in other peripheral tissues, Neuropeptide Y plays pivotal roles in regulating appetite, blood pressure, cardiac contractility, intestinal secretion, and stem-cell biology[1-2]. Neuropeptide Y modulates cellular functions of NK-cells, and circulating levels of Neuropeptide Y are correlated with NK activity[3].
In vitro, neurons were pretreated with Neuropeptide Y (0.5, 1, and 2μM) for 24h and then exposed to Aβ’s pathogenic fragment 25-35 (Aβ25-35) (50μM) for 48h. At 24 and 48h, 2μM Neuropeptide Y completely abolished Aβ25-35 induced toxicity, and comparable neuroprotective effects on neuronal survival were seen with 1μM and 0.5μM pretreatments[4]. After 24h of treatment with Neuropeptide Y (0, 20, or 200nM), bone-marrow-derived macrophages (BMMs) exhibited a significant up-regulation of matrix metalloproteinases (MMPs)-3 mRNA expression and protein secretion[5].
In vivo, following intracerebral administration of Neuropeptide Y (0, 24, 78, 156, or 235pmol in 5μl), rats receiving injections into the perifornical hypothalamus (PFH) consumed significantly more food than those injected into the nucleus accumbens (NAC), and a clear dose-dependent effect was also observed[6]. Central administration of Neuropeptide Y (4.5nmol) to male Sprague-Dawley rats significantly elevated NAC dopamine (DA) release to 150% of baseline and produced a step-wise increase in NAC norepinephrine efflux[7].
References:
[1] Peng S, Zhou YL, Song ZY, Lin S. Effects of Neuropeptide Y on Stem Cells and Their Potential Applications in Disease Therapy. Stem Cells Int. 2017;2017:6823917.
[2] Li C, Wu X, Liu S, Zhao Y, Zhu J, Liu K. Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases. Front Neurosci. 2019;13:869.
[3] Bedoui S, Lechner S, Gebhardt T, et al. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. J Neuroimmunol. 2002;132(1-2):25-33.
[4] Croce N, Ciotti MT, Gelfo F, et al. Neuropeptide Y protects rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem Neurosci. 2012;3(4):312-318.
[5] Choi B, Shin MK, Kim EY, et al. Elevated Neuropeptide Y in Endothelial Dysfunction Promotes Macrophage Infiltration and Smooth Muscle Foam Cell Formation. Front Immunol. 2019;10:1701.
[6] Brown CM, Coscina DV, Fletcher PJ. The rewarding properties of neuropeptide Y in perifornical hypothalamus vs. nucleus accumbens. Peptides. 2000;21(8):1279-1287.
[7] Quarta D, Leslie CP, Carletti R, Valerio E, Caberlotto L. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas. Neuropharmacology. 2011;60(2-3):328-335.
Neuropeptide Y (29-64), amide, human，一种由36个氨基酸组成的肽，可与五种G蛋白偶联受体（Y1、Y2、Y4、Y5和y6）结合。Neuropeptide Y广泛分布于中枢与外周神经系统及其他外周组织，Neuropeptide Y在调控食欲、血压、心肌收缩力、肠道分泌和干细胞生物学中发挥关键作用[1-2]。Neuropeptide Y还能调节NK细胞的细胞功能，且循环Neuropeptide Y水平与NK活性呈正相关[3]。
在体外，神经元先用Neuropeptide Y（0.5、1、2μM）预处理24h，再用Aβ的致病片段25-35（Aβ25-35，50μM）处理48h。在24和48h时，2μM Neuropeptide Y完全抵消了Aβ25-35诱导的毒性，1μM和0.5μM预处理亦产生类似的神经保护作用[4]。骨髓来源巨噬细胞（BMMs）经Neuropeptide Y（0、20或200nM）处理24h后，基质金属蛋白酶-3（MMP-3）的mRNA表达及蛋白分泌显著上调[5]。
在体内，经脑内给予Neuropeptide Y（0、24、78、156或235pmol，5μl）后，注射至下丘脑摄食区（PFH）的大鼠摄食量显著高于注射至伏隔核（NAC）的大鼠，且呈现明显的剂量依赖性[6]。向雄性Sprague-Dawley大鼠中枢注射Neuropeptide Y（4.5nmol）可将伏隔核多巴胺（DA）释放量提升至基线的150%，并使伏隔核去甲肾上腺素（NE）外排呈阶梯式增加[7]。
| Cell experiment [1]: | |
Cell lines | neurons |
Preparation Method | Primary cortical neurons were preincubated either alone (positive control) or with three concentrations of Neuropeptide Y (0.5, 1, and 2μM) for 24h and then exposed to Aβ’s pathogenic fragment 25-35 (Aβ25-35) (50μM) for 48h. At 24 and 48h, neuronal survival was evaluated with the MTS assay. |
Reaction Conditions | 0.5, 1, and 2μM; 24h, 48h |
Applications | After 48h of incubation, Aβ25-35 significantly reduced cell viability. Neuropeptide Y was able to protect cortical neurons from Aβ25-35 toxicity. We found that 2μM Neuropeptide Y abolished the toxic effects of Aβ25-35 at 24 and 48h. The same effect on neuronal survival was observed in neurons exposed to 1μM and 0.5μM Neuropeptide Y pretreatments. |
| Animal experiment [2]: | |
Animal models | male Sprague-Dawley rats |
Preparation Method | All rats were acclimated to central injections by gently restraining them within a towel and performing sham injections at least twice on separate days before testing began. On each test day, subjects were pre-satiated by removing all food pellets from the cage hoppers and placing four or five chow pellets on the cage floors. One hour later, testing with Neuropeptide Y began. Neuropeptide Y (0, 24, 78, 156 or 235pmol per injection side) was dissolved in sterile physiological saline (0.9%) and injected in a volume of 0.5μl using a 28-gauge (0.18mm diameter) stainless steel injector cut to terminate 3mm below each guide cannula. The injector was attached to a 5μl microsyringe by a length of plastic tubing. All solutions were infused manually over a period of 1min, and the injector was left inside the guide cannula for an additional 30sec to permit diffusion. Testing began immediately following injections. Intake (g) minus spillage was measured 1 and 2h post-injection. There were at least two Neuropeptide Y-free days interspersed between each testing session. |
Dosage form | 0, 24, 78, 156 or 235pmol 0.5μl; Intracerebral drug administration |
Applications | At both the 1h and 2h time points, cumulative intake in the eriforinal hypothalamus (PFH)-treated rats was markedly higher than in the nucleus accumbens (NAC)-treated group, and a significant main effect of dose was also observed. |
References: | |
| Cas No. | 90880-35-6 | SDF | |
| 别名 | 神经肽-Y(人,鼠),NPY (human, rat) | ||
| Canonical SMILES | Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 | ||
| 分子式 | C189H285N55O57S | 分子量 | 4271.68 |
| 溶解度 | 30mg/ml in ethanol, DMSO, DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2341 mL | 1.1705 mL | 2.341 mL |
| 5 mM | 0.0468 mL | 0.2341 mL | 0.4682 mL |
| 10 mM | 0.0234 mL | 0.117 mL | 0.2341 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet